LU84632A1 - Stabilisierte insulinloesungen und verfahren zu ihrer herstellung - Google Patents

Stabilisierte insulinloesungen und verfahren zu ihrer herstellung Download PDF

Info

Publication number: LU84632A1
Authority: LU; Luxembourg
Prior art keywords: insulin; zinc; solution according; solution; hexamer
Prior art date: 1982-02-05

Application number

LU84632A

Other languages

German (de)

English (en)

Inventor

Svend Havelund

Joergen Vejlgaard Brange Jens

Original Assignee

Novo Industri As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-02-05

Filing date

1983-02-04

Publication date

1983-09-08

1983-02-04 Application filed by Novo Industri As filed Critical Novo Industri As

1983-09-08 Publication of LU84632A1 publication Critical patent/LU84632A1/fr

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 316
229940125396 insulin Drugs 0.000 claims description 154
108090001061 Insulin Proteins 0.000 claims description 148
102000004877 Insulin Human genes 0.000 claims description 148
239000011701 zinc Substances 0.000 claims description 107
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 65
229910052725 zinc Inorganic materials 0.000 claims description 65
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 37
239000008139 complexing agent Substances 0.000 claims description 28
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical group [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 12
239000004246 zinc acetate Substances 0.000 claims description 12
239000004471 Glycine Substances 0.000 claims description 10
235000011187 glycerol Nutrition 0.000 claims description 10
239000003755 preservative agent Substances 0.000 claims description 10
150000003751 zinc Chemical class 0.000 claims description 10
230000002335 preservative effect Effects 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 5
239000006179 pH buffering agent Substances 0.000 claims description 5
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
101710186643 Insulin-2 Proteins 0.000 claims description 3
239000000872 buffer Substances 0.000 claims description 2
239000007951 isotonicity adjuster Substances 0.000 claims description 2
239000011592 zinc chloride Substances 0.000 claims description 2
235000005074 zinc chloride Nutrition 0.000 claims description 2
229920001202 Inulin Polymers 0.000 claims 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
229940029339 inulin Drugs 0.000 claims 1
239000000243 solution Substances 0.000 description 83
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
238000002360 preparation method Methods 0.000 description 13
238000001914 filtration Methods 0.000 description 11
239000007864 aqueous solution Substances 0.000 description 9
230000000694 effects Effects 0.000 description 7
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 7
238000012360 testing method Methods 0.000 description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
101000976075 Homo sapiens Insulin Proteins 0.000 description 6
108010005991 Pork Regular Insulin Proteins 0.000 description 6
238000000034 method Methods 0.000 description 6
108010066090 neutral insulin Proteins 0.000 description 5
101000993800 Sus scrofa Insulin Proteins 0.000 description 4
238000013112 stability test Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
206010061592 cardiac fibrillation Diseases 0.000 description 3
239000013078 crystal Substances 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
230000002600 fibrillogenic effect Effects 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000005086 pumping Methods 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
101001011741 Bos taurus Insulin Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
QNDQILQPPKQROV-UHFFFAOYSA-N dizinc Chemical compound [Zn]=[Zn] QNDQILQPPKQROV-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
235000014304 histidine Nutrition 0.000 description 2
238000001802 infusion Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229940119528 pork insulin Drugs 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010008488 Glycylglycine Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000011282 treatment Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
- H05K13/00—Apparatus or processes specially adapted for manufacturing or adjusting assemblages of electric components
- H05K13/06—Wiring by machine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Manufacturing & Machinery (AREA)
Microelectronics & Electronic Packaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

LU84632A 1982-02-05 1983-02-04 Stabilisierte insulinloesungen und verfahren zu ihrer herstellung LU84632A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK49182		1982-02-05
DK49182		1982-02-05

Publications (1)

Publication Number	Publication Date
LU84632A1 true LU84632A1 (fr)	1983-09-08

Family

ID=8094159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU84632A LU84632A1 (fr)	1982-02-05	1983-02-04	Stabilisierte insulinloesungen und verfahren zu ihrer herstellung

Country Status (22)

Country	Link
US (1)	US4476118A (fr)
JP (1)	JPS58192818A (fr)
AT (1)	AT382780B (fr)
AU (1)	AU549981B2 (fr)
BE (1)	BE895832A (fr)
CA (1)	CA1203476A (fr)
CH (1)	CH657530A5 (fr)
DE (1)	DE3303860A1 (fr)
ES (1)	ES519533A0 (fr)
FI (1)	FI78616C (fr)
FR (1)	FR2521009B1 (fr)
GB (1)	GB2114573B (fr)
GR (1)	GR77388B (fr)
IE (1)	IE54548B1 (fr)
IT (1)	IT1178455B (fr)
LU (1)	LU84632A1 (fr)
NL (1)	NL187269C (fr)
NO (1)	NO161204C (fr)
NZ (1)	NZ203189A (fr)
PT (1)	PT76195B (fr)
SE (1)	SE460948B (fr)
ZA (1)	ZA83742B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE50502T1 (de) *	1984-06-09	1990-03-15	Hoechst Ag	Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
JP2520262B2 (ja) *	1987-08-21	1996-07-31	春幸川原	パツチテスト材料
US4789660A (en) *	1987-09-10	1988-12-06	American Home Products Corporation	Insulin administration using methyl and propyl paraben
US5130298A (en) *	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
US5534488A (en) *	1993-08-13	1996-07-09	Eli Lilly And Company	Insulin formulation
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
YU18596A (sh) *	1995-03-31	1998-07-10	Eli Lilly And Company	Analogne formulacije monomernog insulina
AU7678196A (en) *	1995-11-13	1997-06-05	Minimed, Inc.	Methods and compositions for the delivery of monomeric proteins
EP0891419A4 (fr) *	1996-03-12	2000-03-01	Life Technologies Inc	Additif pour milieu de culture nutritif pour cellules hematopoietiques
DK0821006T3 (da) *	1996-07-26	2004-08-16	Aventis Pharma Gmbh	Insulinderivater med öget zinkbinding
ZA984697B (en) *	1997-06-13	1999-12-01	Lilly Co Eli	Stable insulin formulations.
SI0884053T1 (en) *	1997-06-13	2003-02-28	Eli Lilly And Company	Stable insulin formulations
DE69826705T2 (de) *	1997-11-12	2006-02-23	Alza Corp., Palo Alto	Verfahren zur dermalen verabreichung von polypeptiden
DE19825447A1 (de)	1998-06-06	1999-12-09	Hoechst Marion Roussel De Gmbh	Neue Insulinanaloga mit erhöhter Zinkbildung
PT1121144E (pt) *	1998-10-16	2002-11-29	Novo Nordisk As	Preparados de insulina concentrada estavel para administracao pulmonar
DE19930676B4 (de) *	1999-07-02	2006-01-19	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
JP2003528149A (ja) *	2000-03-24	2003-09-24	ジェネンテック・インコーポレーテッド	軟骨性疾患の治療のためのインスリンの使用
JP4147234B2 (ja) *	2004-09-27	2008-09-10	キヤノン株式会社	吐出用液体、吐出方法、カートリッジ及び吐出装置
ATE496064T1 (de)	2002-05-07	2011-02-15	Novo Nordisk As	Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US20050065066A1 (en) *	2002-12-20	2005-03-24	Kaarsholm Niels Christian	Stabilised insulin compositions
AU2003291972A1 (en) *	2002-12-20	2004-07-14	Novo Nordisk A/S	Pharmaceutical compositions comprising insulin and legends of insulin hexamer
WO2004096266A1 (fr) *	2003-05-02	2004-11-11	Novo Nordisk A/S	Stabilite physique amelioree de preparations d'insuline
KR101159559B1 (ko) *	2003-08-05	2012-06-26	노보 노르디스크 에이/에스	신규의 인슐린 유도체
MX2007000883A (es) *	2004-07-19	2007-04-02	Biocon Ltd	Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
US20090136538A1 (en) *	2006-05-22	2009-05-28	Jan Jezek	Stable vaccine formulation
GB0700523D0 (en) *	2007-01-11	2007-02-21	Insense Ltd	The Stabilisation Of Proteins
ES2579229T3 (es)	2007-03-13	2016-08-08	Jds Therapeutics, Llc	Procedimientos y composiciones para la liberación sostenida de cromo
WO2008152106A1 (fr) *	2007-06-13	2008-12-18	Novo Nordisk A/S	Formulation pharmaceutique contenant un dérivé d'insuline
WO2009002867A2 (fr)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
ES2612736T3 (es) *	2007-11-16	2017-05-18	Novo Nordisk A/S	Composiciones farmacéuticas estables que comprenden liraglutida y degludec
EP2341940A1 (fr) *	2008-07-16	2011-07-13	Arecor Limited	Stabilisation des proteines
EP2328607A1 (fr) *	2008-07-16	2011-06-08	Arecor Limited	Formulation stable d'une protéine thérapeutique
CA2738615A1 (fr) *	2008-10-30	2010-05-06	Novo Nordisk A/S	Traitement du diabete a l'aide d'injections d'insuline avec une frequence inferieure a une injection par jour
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
JP6049625B2 (ja)	2010-10-27	2016-12-21	ノヴォノルディスクアー／エス	様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
AU2012223282B2 (en)	2011-03-01	2017-02-02	Nutrition 21, Llc	Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
KR20150082640A (ko)	2012-11-13	2015-07-15	아도시아	치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
MX360420B (es) *	2012-12-19	2018-10-31	Wockhardt Ltd	Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
MX2015006997A (es)	2012-12-26	2015-09-23	Wockhardt Ltd	Composicion farmaceutica.
TWI641381B (zh) *	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014177623A1 (fr)	2013-04-30	2014-11-06	Novo Nordisk A/S	Schéma d'administration d'un nouveau type
WO2015084694A2 (fr) *	2013-12-04	2015-06-11	Merck Sharp & Dohme Corp.	Procédé de préparation d'insuline cristalline
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
JO3749B1 (ar)	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
AU2017217466A1 (en)	2016-02-11	2018-08-23	Nutrition 21, Llc	Chromium containing compositions for improving health and fitness
AU2017334290B2 (en) *	2016-09-29	2023-04-20	Arecor Limited	Novel formulations
WO2018222787A1 (fr)	2017-06-01	2018-12-06	Eli Lilly And Company	Compositions d'insuline à action rapide
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
CN114887039B (zh) *	2022-05-13	2026-01-30	西北工业大学	一种锌离子介导的自组装胰岛素纳米药物、制备方法和应用
CN120142500B (zh) *	2025-02-28	2025-10-10	中国计量科学研究院	一种具有互换性的活性人胰岛素溶液标准物质及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2882202A (en) *	1950-04-05	1959-04-14	Novo Terapeutisk Labor As	Insulin crystal preparations and methods of producing them
US2787575A (en) *	1950-11-22	1957-04-02	Organon	Zinc-glycine-insulin composition and production thereof
US2882203A (en) *	1951-06-26	1959-04-14	Novo Terapeutisk Labor As	Injectable insulin preparation with protracted effect
DE1044360B (de) *	1953-08-19	1958-11-20	Roskilde Medical Company Ltd R	Verfahren zur Herstellung von Zinkinsulin mit erhoehtem Zinkgehalt
DE956098C (de) *	1954-02-18	1957-01-10	Dr Dr Guenther Weitzel	Verfahren zur Herstellung zinkreicher Insulin-Komplexverbindungen
US3058885A (en) *	1957-06-08	1962-10-16	Novo Terapeutisk Labor As	Process for treatment of insulin crystals and for production of insulin preparationstherefrom
US3014842A (en) *	1957-08-10	1961-12-26	Novo Terapeutish Lab A S	Injectable bovine insulin crystal suspensions and process of producing same
US3091573A (en) *	1958-05-12	1963-05-28	Novo Terapeutisk Labor As	Quick acting insulin preparation
FR1263220A (fr) *	1958-08-01	1961-06-09	Novo Terapeutisk Labor As	Procédé de production d'une préparation d'insuline à action rapide
DK116527B (da) *	1967-03-01	1970-01-19	Nordisk Insulinlab	Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
GB1285023A (en) *	1968-08-09	1972-08-09	Novo Terapeutisk Labor As	Improvements in or relating to injectable insulin preparations
US3657425A (en) *	1969-03-12	1972-04-18	Burroughs Wellcome Co	Beef insulin preparations
DE2459515C3 (de) *	1974-12-17	1982-02-11	Hoechst Ag, 6000 Frankfurt	Arzneimittelzubereitungen mit antidiabetischer Wirkung
DE3064888D1 (en) *	1979-04-30	1983-10-27	Hoechst Ag	Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
DK80781A (da) *	1980-02-29	1981-08-30	Hospital For Sick Children	Oploesninger af polypeptider
ES520249A0 (es) *	1982-03-03	1984-04-16	Nordisk Insulinlab	Procedimiento de producir preparaciones de insulina.

1983
- 1983-02-03 FI FI830375A patent/FI78616C/fi not_active IP Right Cessation
- 1983-02-04 LU LU84632A patent/LU84632A1/fr unknown
- 1983-02-04 NZ NZ203189A patent/NZ203189A/en unknown
- 1983-02-04 GR GR70416A patent/GR77388B/el unknown
- 1983-02-04 BE BE6/47775A patent/BE895832A/fr not_active IP Right Cessation
- 1983-02-04 FR FR8301790A patent/FR2521009B1/fr not_active Expired
- 1983-02-04 CH CH657/83A patent/CH657530A5/de not_active IP Right Cessation
- 1983-02-04 IE IE220/83A patent/IE54548B1/en not_active IP Right Cessation
- 1983-02-04 SE SE8300598A patent/SE460948B/sv not_active IP Right Cessation
- 1983-02-04 IT IT19420/83A patent/IT1178455B/it active
- 1983-02-04 AT AT0038983A patent/AT382780B/de not_active IP Right Cessation
- 1983-02-04 DE DE19833303860 patent/DE3303860A1/de active Granted
- 1983-02-04 JP JP58016303A patent/JPS58192818A/ja active Granted
- 1983-02-04 ZA ZA83742A patent/ZA83742B/xx unknown
- 1983-02-04 NL NLAANVRAGE8300440,A patent/NL187269C/xx not_active IP Right Cessation
- 1983-02-04 ES ES519533A patent/ES519533A0/es active Granted
- 1983-02-04 CA CA000420907A patent/CA1203476A/fr not_active Expired
- 1983-02-04 AU AU11136/83A patent/AU549981B2/en not_active Expired
- 1983-02-04 PT PT76195A patent/PT76195B/pt unknown
- 1983-02-04 GB GB08303133A patent/GB2114573B/en not_active Expired
- 1983-02-04 US US06/463,730 patent/US4476118A/en not_active Expired - Lifetime
- 1983-02-04 NO NO830385A patent/NO161204C/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA1203476A (fr)	1986-04-22
GB2114573B (en)	1985-05-01
US4476118A (en)	1984-10-09
IE54548B1 (en)	1989-11-08
FR2521009A1 (fr)	1983-08-12
IT1178455B (it)	1987-09-09
JPS58192818A (ja)	1983-11-10
CH657530A5 (de)	1986-09-15
GB8303133D0 (en)	1983-03-09
IT8319420A0 (it)	1983-02-04
PT76195B (en)	1986-01-27
ZA83742B (en)	1983-11-30
AU1113683A (en)	1983-08-11
FI830375A0 (fi)	1983-02-03
PT76195A (en)	1983-03-01
DE3303860C2 (fr)	1989-12-28
FI830375L (fi)	1983-08-06
FI78616C (fi)	1989-09-11
BE895832A (fr)	1983-08-04
NO161204C (no)	1989-07-19
JPH0367056B2 (fr)	1991-10-21
FR2521009B1 (fr)	1987-07-17
FI78616B (fi)	1989-05-31
NO830385L (no)	1983-08-08
NL8300440A (nl)	1983-09-01
SE8300598D0 (sv)	1983-02-04
NZ203189A (en)	1985-07-31
NO161204B (no)	1989-04-10
NL187269C (nl)	1991-08-01
ES8500060A1 (es)	1984-10-16
NL187269B (nl)	1991-03-01
IE830220L (en)	1983-08-05
GB2114573A (en)	1983-08-24
SE460948B (sv)	1989-12-11
ATA38983A (de)	1986-09-15
SE8300598L (sv)	1983-08-06
AU549981B2 (en)	1986-02-20
ES519533A0 (es)	1984-10-16
AT382780B (de)	1987-04-10
GR77388B (fr)	1984-09-11
DE3303860A1 (de)	1983-08-18

Publication	Publication Date	Title
DE3303860C2 (fr)	1989-12-28
AT408611B (de)	2002-01-25	Insulinanalogon-protamin-komplex
AT408720B (de)	2002-02-25	Parenterale pharmazeutische formulierung eines humaninsulinanalogon-komplexes
EP0357978B1 (fr)	1992-05-13	Préparation pharmaceutique pour le traitement du diabète sucré
DE69708121T2 (de)	2002-08-01	Halogenid-enthaltende insulinzubereitungen
DE69428860T2 (de)	2002-05-02	Insulin Formulierung
DE69834956T2 (de)	2007-05-24	Stabile Insulinformulierungen
DE3240177C2 (fr)	1993-07-22
DE69434963T2 (de)	2008-01-17	Selektiv auf die leber wirkende pharmazeutisch aktive substanz
EP2305288B1 (fr)	2020-07-15	Préparations d'insuline amères dotées d'une stabilité améliorée
EP0065747B1 (fr)	1986-10-15	Nonapeptide pour le traitement de troubles causés par la désaccoutumance de stupéfiants
DE10114178A1 (de)	2002-10-10	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE69115590T2 (de)	1996-08-01	4-Chinolonderivate mit einem zweiwertigen Metallion komplexiert enthaltende Zusammensetzung
CH652031A5 (de)	1985-10-31	Stabilisierte insulinpraeparate und verfahren zu deren herstellung.
DE3837825A1 (de)	1990-05-10	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
EP3202394A1 (fr)	2017-08-09	Préparations aqueuses de l´insuline contenant de la méthionine
DE69827357T2 (de)	2005-11-24	Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
EP2451472A1 (fr)	2012-05-16	Préparations d'insuline stables à la chaleur et aux agitations
EP2451471A1 (fr)	2012-05-16	Préparations d'insuline à effet retard
EP0291863B1 (fr)	1992-01-22	Cristaux mixtes d'insuline et dérivés d'insuline, procédé pour la préparation de ces cristaux mixtes et agents pharmaceutiques les contenant
EP0166971B1 (fr)	1990-02-28	Préparations d'insuline, procédé pour leur fabrication et leur application
DE1212679B (de)	1966-03-17	Verfahren zur Herstellung von Insulinloesungen
EP0187361A2 (fr)	1986-07-16	Compositions à libération prolongée, procédé de préparation et compositions appropriées pour application médicinale ou vétérinaire
DE60001489T2 (de)	2003-12-04	Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
AT401469B (de)	1996-09-25	Pharmazeutische wässrige lösung zur parenteralen anwendung enthaltend einen in situ gebildeten komplex von einem alkaloid mit bis-indol-gerüst, sowie verfahren zu deren herstellung